Michael Surace
YOU?
Author Swipe
View article: 1240 Tumor cells expressing CD68 correlates with EMT, reduced CD8+ T cell migration, and elevated immuno-oncology markers in hepatocellular carcinoma
1240 Tumor cells expressing CD68 correlates with EMT, reduced CD8+ T cell migration, and elevated immuno-oncology markers in hepatocellular carcinoma Open
View article: Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing Open
Objectives Multiplex immunohistochemistry and immunofluorescence (mIHC/IF) are emerging technologies that can be used to help define complex immunophenotypes in tissue, quantify immune cell subsets, and assess the spatial arrangement of ma…
View article: 1371 Tumoral CD68 expression associates with epithelial-to-mesenchymal transition and correlates with decreased CD68 T cell migration
1371 Tumoral CD68 expression associates with epithelial-to-mesenchymal transition and correlates with decreased CD68 T cell migration Open
View article: Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring
Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring Open
Tertiary Lymphoid Structures (TLS) are lymphoid structures commonly associated with improved survival of cancer patients and response to immunotherapies. However, conflicting reports underscore the need to consider TLS heterogeneity and mu…
View article: The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment Open
View article: Data from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Data from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial Open
Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-free survival in patients with resectable non–small cell lung cancer (NSCLC) versus chemotherapy alone. NeoCOAST was the first randomized, multidrug platfo…
View article: Supplementary Data - Supplementary Table 7 from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Supplementary Data - Supplementary Table 7 from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial Open
Supplementary Table 7. Tumor RNA sequencing. (File too large to be included in main supplementary file).
View article: Supplementary Appendix from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Supplementary Appendix from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial Open
Additional details on safety endpoints. Supplementary tables: 1, Representativeness of study participants; 2, Efficacy summary; 3, Adverse events occurring in ≥10% of patients; 4, Treatment-related adverse events occurring in ≥5% of patien…
View article: Data from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Data from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial Open
Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-free survival in patients with resectable non–small cell lung cancer (NSCLC) versus chemotherapy alone. NeoCOAST was the first randomized, multidrug platfo…
View article: Supplementary Data - Supplementary Table 7 from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Supplementary Data - Supplementary Table 7 from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial Open
Supplementary Table 7. Tumor RNA sequencing. (File too large to be included in main supplementary file).
View article: Supplementary Appendix from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Supplementary Appendix from Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial Open
Additional details on safety endpoints. Supplementary tables: 1, Representativeness of study participants; 2, Efficacy summary; 3, Adverse events occurring in ≥10% of patients; 4, Treatment-related adverse events occurring in ≥5% of patien…
View article: 1505 Spatial profiling of the SCLC tumor microenvironment defined by high MHC-I expression reveals association with functionally relevant antigen presentation
1505 Spatial profiling of the SCLC tumor microenvironment defined by high MHC-I expression reveals association with functionally relevant antigen presentation Open
Background Small cell lung cancer (SCLC) is an aggressive and largely immune-cold cancer type, for which chemotherapy combined with Immuno-oncology (IO) therapies is providing benefit only in a subgroup of patients. SCLC is a highly hetero…
View article: Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial Open
Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-free survival in patients with resectable non–small cell lung cancer (NSCLC) versus chemotherapy alone. NeoCOAST was the first randomized, multidrug platfo…
View article: 155 MHC class I antigen presentation is associated with an inflamed SCLC tumor microenvironment characterized by a higher density of cytotoxic T-cells in closer proximity to tumor cells
155 MHC class I antigen presentation is associated with an inflamed SCLC tumor microenvironment characterized by a higher density of cytotoxic T-cells in closer proximity to tumor cells Open
Background Small cell lung cancer (SCLC) is generally known to exclude immune cells and durable responses to immunotherapies are rare. Only very few biomarkers to inform immuno-oncology (IO) treatments are established in clinical practice …
View article: Cellular inhibitor of apoptosis 2 (cIAP2) restricts neuroinflammation during experimental autoimmune encephalomyelitis
Cellular inhibitor of apoptosis 2 (cIAP2) restricts neuroinflammation during experimental autoimmune encephalomyelitis Open
Background Immune activation, neuroinflammation, and cell death are the hallmarks of multiple sclerosis (MS), which is an autoimmune demyelinating disease of the central nervous system (CNS). It is well-documented that the cellular inhibit…
View article: 822 GraphITE: unsupervised graph embeddings approach to multiplex immunofluorescence image exploration reveals new insights into NSCLC and HNSCC tumor microenvironment
822 GraphITE: unsupervised graph embeddings approach to multiplex immunofluorescence image exploration reveals new insights into NSCLC and HNSCC tumor microenvironment Open
Background Predictive biomarkers for response to IO therapies remain insufficient. Although multiplex immunofluorescence has the potential to provide superior biomarkers, the information garnered from these studies is frequently underlever…
View article: 39 A multi-modal analysis approach leveraging multiplexed spatial phenotyping and multi-omics analysis to better understand the prognostic value of tertiary lymphoid structures in NSCLC
39 A multi-modal analysis approach leveraging multiplexed spatial phenotyping and multi-omics analysis to better understand the prognostic value of tertiary lymphoid structures in NSCLC Open
Background Tertiary Lymphoid Structures (TLS) are highly organized ectopic lymphoid structures found in inflamed or tumor tissues, acting as sites of lymphoid recruitment and immune activation. A high TLS density within the tumor is common…
View article: An Unsupervised Graph Embeddings Approach to Multiplex Immunofluorescence Image Exploration
An Unsupervised Graph Embeddings Approach to Multiplex Immunofluorescence Image Exploration Open
Understanding the complex biology of the tumor microenvironment (TME) is necessary to understand the mechanisms of action of immuno-oncology therapies and to match the right therapies to the right patients. Multiplex immunofluorescence (mI…
View article: The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation Open
Objectives The interaction between the immune system and tumor cells is an important feature for the prognosis and treatment of cancer. Multiplex immunohistochemistry (mIHC) and multiplex immunofluorescence (mIF) analyses are emerging tech…
View article: Correction: Cellular cytotoxicity is a form of immunogenic cell death
Correction: Cellular cytotoxicity is a form of immunogenic cell death Open
View article: Insights into the tumour immune microenvironment using tissue phenomics to drive cancer immunotherapy
Insights into the tumour immune microenvironment using tissue phenomics to drive cancer immunotherapy Open
View article: P1.09-16 Tumor Proliferation Is Associated with the Tumor Immunological Status: A Study on NSCLC Using Multiplex Immunofluorescence
P1.09-16 Tumor Proliferation Is Associated with the Tumor Immunological Status: A Study on NSCLC Using Multiplex Immunofluorescence Open
View article: Abstract 491: Tumor heterogeneity and its impact on immunoprofiling data: Whole tumor vs regions of interest (ROI) analysis of multiplex immunofluorescence in four carcinoma types
Abstract 491: Tumor heterogeneity and its impact on immunoprofiling data: Whole tumor vs regions of interest (ROI) analysis of multiplex immunofluorescence in four carcinoma types Open
Background: Multiplex immunofluorescence (mIF) is a key tool for cancer immunoprofiling in tissue samples. These techniques typically require an investigator to select regions of interest (ROI) within the tumor for digital image analysis. …
View article: RelB controls adaptive responses of astrocytes during sterile inflammation
RelB controls adaptive responses of astrocytes during sterile inflammation Open
In response to brain injury or infections, astrocytes become reactive, undergo striking morphological and functional changes, and secrete and respond to a spectrum of inflammatory mediators. We asked whether reactive astrocytes also displa…
View article: Atypical microglial response to biodiesel exhaust in healthy and hypertensive rats
Atypical microglial response to biodiesel exhaust in healthy and hypertensive rats Open
View article: Sphingosine‐1‐phosphate inhibits IL‐1‐induced expression of C‐C motif ligand 5 <i>via</i> c‐Fos‐dependent suppression of IFN‐β amplification loop
Sphingosine‐1‐phosphate inhibits IL‐1‐induced expression of C‐C motif ligand 5 <i>via</i> c‐Fos‐dependent suppression of IFN‐β amplification loop Open
The neuroinflammation associated with multiple sclerosis involves activation of astrocytes that secrete and respond to inflammatory mediators such as IL‐1. IL‐1 stimulates expression of many chemokines, including C‐C motif ligand (CCL) 5, …
View article: RelB/p50 Complexes Regulate Cytokine-Induced YKL-40 Expression
RelB/p50 Complexes Regulate Cytokine-Induced YKL-40 Expression Open
The secreted protein, YKL-40, has been proposed as a biomarker of a variety of human diseases characterized by ongoing inflammation, including chronic neurologic pathologies such as multiple sclerosis and Alzheimer’s disease. However, infl…